交易 Assembly Biosciences, Inc. - ASMB CFD
加入收藏夹- 概括
- 曆史數據
- 活動
- 收入報表
- 資産負債表
- 現金流
交易條件
价差 | 0.2552 | ||||||||
多头隔夜费
多头隔夜费
前往平台 | -0.026179% | ||||||||
空头隔夜费
空头隔夜费
前往平台 | 0.003957% | ||||||||
隔夜费时间 | 21:00 (UTC) | ||||||||
最小交易量 | 0.001 | ||||||||
货币 | USD | ||||||||
保证金 | 5% | ||||||||
上市交易所 | United States of America | ||||||||
交易费 | 0% |
*Information provided by Capital.com
Assembly Biosciences Inc ESG Risk Ratings
High Medium Low Negligible
“C”分數表示在公開報告重大 ESG 數據方面令人滿意的相對 ESG 表現和適度的透明度。
- 上週
- 上個月
- 去年
- 過去兩年
- 最大
- 每日
- 每週
- 每月
日期 | 關閉 | 更改 | 變化 (%) | 打開 | 高 | 低 |
---|---|---|---|---|---|---|
Mar 28, 2024 | 13.2474 | 0.2400 | 1.85% | 13.0074 | 13.4474 | 12.9974 |
Mar 27, 2024 | 13.3074 | 0.5800 | 4.56% | 12.7274 | 13.3674 | 12.7174 |
Mar 26, 2024 | 12.8474 | -0.4500 | -3.38% | 13.2974 | 13.3974 | 12.7374 |
Mar 25, 2024 | 12.9974 | 0.4900 | 3.92% | 12.5074 | 13.3674 | 12.5074 |
Mar 22, 2024 | 12.5474 | 0.5500 | 4.58% | 11.9974 | 12.8474 | 11.9974 |
Mar 21, 2024 | 12.1574 | 0.3000 | 2.53% | 11.8574 | 12.6074 | 11.8474 |
Mar 20, 2024 | 12.0974 | 0.2500 | 2.11% | 11.8474 | 12.0974 | 11.8474 |
Mar 19, 2024 | 11.8274 | 0.0800 | 0.68% | 11.7474 | 11.9774 | 11.7474 |
Mar 18, 2024 | 11.7474 | 0.1500 | 1.29% | 11.5974 | 12.0974 | 11.5974 |
Mar 15, 2024 | 11.9474 | 0.2000 | 1.70% | 11.7474 | 12.0274 | 11.3474 |
Mar 14, 2024 | 12.0474 | -0.4700 | -3.75% | 12.5174 | 12.5174 | 11.6474 |
Mar 13, 2024 | 12.5974 | 0.1000 | 0.80% | 12.4974 | 12.8374 | 12.4974 |
Mar 12, 2024 | 12.7674 | 0.0200 | 0.16% | 12.7474 | 12.9874 | 12.7474 |
Mar 11, 2024 | 13.0974 | 0.1000 | 0.77% | 12.9974 | 13.4474 | 12.9974 |
Mar 8, 2024 | 12.7074 | -0.3300 | -2.53% | 13.0374 | 13.3574 | 12.7074 |
Mar 7, 2024 | 13.0974 | 0.0000 | 0.00% | 13.0974 | 13.2974 | 12.6874 |
Mar 6, 2024 | 12.7174 | -0.7300 | -5.43% | 13.4474 | 13.4474 | 12.7174 |
Mar 5, 2024 | 13.1974 | 0.2000 | 1.54% | 12.9974 | 13.1974 | 12.5874 |
Mar 4, 2024 | 13.1474 | 0.0900 | 0.69% | 13.0574 | 13.6674 | 12.9974 |
Mar 1, 2024 | 13.2574 | 0.7800 | 6.25% | 12.4774 | 13.4074 | 12.3474 |
Assembly Biosciences, Inc. Events
时间(协调世界时) (UTC) | 国家 | 事件 |
---|---|---|
Thursday, May 2, 2024 | ||
时间(协调世界时) (UTC) 10:59 | 国家 US
| 事件 Q1 2024 Assembly Biosciences Inc Earnings Release Q1 2024 Assembly Biosciences Inc Earnings ReleaseForecast(预报) -上一页 - |
Friday, May 24, 2024 | ||
时间(协调世界时) (UTC) 15:00 | 国家 US
| 事件 Assembly Biosciences Inc Annual Shareholders Meeting Assembly Biosciences Inc Annual Shareholders MeetingForecast(预报) -上一页 - |
- 年度
- 每季度
2022 | 2021 | 2020 | 2019 | 2018 | |
---|---|---|---|---|---|
總收入 | 0 | 6.254 | 79.105 | 15.963 | 14.804 |
總營業費用 | 94.114 | 138.942 | 143.881 | 118.676 | 107.539 |
銷售/一般/行政費用,總計 | 23.906 | 28.503 | 36.86 | 32.919 | 34.798 |
研究與開發 | 69.111 | 70.149 | 101.337 | 85.757 | 72.741 |
營業收入 | -94.114 | -132.688 | -64.776 | -102.713 | -92.735 |
利息收入(費用),非經營淨值 | 1.022 | 0.302 | 2.624 | 4.3 | 3.083 |
稅前淨收入 | -93.092 | -132.386 | -62.152 | -98.408 | -89.652 |
稅後淨收入 | -93.092 | -129.855 | -62.152 | -97.634 | -90.751 |
未計算非常項目前的淨收益 | -93.092 | -129.855 | -62.152 | -97.634 | -90.751 |
淨收入 | -93.092 | -129.855 | -62.152 | -97.634 | -90.751 |
普通股股東可獲收益 (不含非經常性項目) | -93.092 | -129.855 | -62.152 | -97.634 | -90.751 |
普通股股東可獲收益 (含非經常性項目) | -93.092 | -129.855 | -62.152 | -97.634 | -90.751 |
攤薄淨收入 | -93.092 | -129.855 | -62.152 | -97.634 | -90.751 |
攤薄後加權平均股 | 48.4093 | 43.2804 | 35.4271 | 26.2588 | 22.8016 |
扣除特別項目的每股攤薄盈利 | -1.92302 | -3.00032 | -1.75436 | -3.71815 | -3.98002 |
每股正常攤薄盈利 | -1.90036 | -2.39523 | -1.59392 | -3.71815 | -3.98002 |
收入 | 0 | 6.254 | 79.105 | 15.963 | 14.804 |
非常規項目總計 | |||||
其他,淨值 | 0.005 | ||||
異常費用(收入) | 1.097 | 40.29 | 5.684 |
Jun 2023 | Mar 2023 | Dec 2022 | Sep 2022 | Jun 2022 | |
---|---|---|---|---|---|
總收入 | 0 | 0 | 0 | 0 | 0 |
收入 | 0 | 0 | |||
總營業費用 | 17.488 | 19.559 | 22.978 | 23.401 | 24.573 |
銷售/一般/行政費用,總計 | 4.965 | 5.012 | 5.897 | 5.271 | 6.781 |
研究與開發 | 12.523 | 14.547 | 15.984 | 18.13 | 17.792 |
異常費用(收入) | 1.097 | ||||
營業收入 | -17.488 | -19.559 | -22.978 | -23.401 | -24.573 |
利息收入(費用),非經營淨值 | 0.592 | 0.609 | 0.583 | 0.256 | 0.112 |
稅前淨收入 | -16.896 | -18.95 | -22.395 | -23.145 | -24.461 |
稅後淨收入 | -16.896 | -18.95 | -22.395 | -23.145 | -24.461 |
未計算非常項目前的淨收益 | -16.896 | -18.95 | -22.395 | -23.145 | -24.461 |
淨收入 | -16.896 | -18.95 | -22.395 | -23.145 | -24.461 |
普通股股東可獲收益 (不含非經常性項目) | -16.896 | -18.95 | -22.395 | -23.145 | -24.461 |
普通股股東可獲收益 (含非經常性項目) | -16.896 | -18.95 | -22.395 | -23.145 | -24.461 |
攤薄淨收入 | -16.896 | -18.95 | -22.395 | -23.145 | -24.461 |
攤薄後加權平均股 | 52.2601 | 51.0125 | 48.7686 | 48.4484 | 48.2935 |
扣除特別項目的每股攤薄盈利 | -0.32331 | -0.37148 | -0.45921 | -0.47772 | -0.50651 |
Dividends per Share - Common Stock Primary Issue | 0 | 0 | 0 | 0 | |
每股正常攤薄盈利 | -0.32331 | -0.37148 | -0.43672 | -0.47772 | -0.50651 |
- 年度
- 每季度
2022 | 2021 | 2020 | 2019 | 2018 | |
---|---|---|---|---|---|
流動資産總額 | 96.967 | 154.204 | 224.493 | 282.78 | 222.502 |
現金和短期投資 | 91.61 | 146.627 | 216.413 | 274.043 | 218.08 |
現金等價物 | 52.418 | 45.627 | 59.444 | 46.732 | 41.471 |
短期投資 | 39.192 | 101 | 156.969 | 227.311 | 176.609 |
預付的費用 | 4.413 | 7.241 | 6.85 | 5.363 | 1.992 |
總資産 | 101.794 | 191.06 | 283.254 | 339.907 | 268.045 |
物業/廠房/設備,總計 - 淨額 | 3.938 | 7.181 | 10.731 | 13.805 | 0.557 |
物業/廠房/設備,總計 - 總額 | 5.625 | 8.388 | 12.567 | 15.005 | 1.614 |
累計折舊,總計 | -1.687 | -1.207 | -1.836 | -1.2 | -1.057 |
商譽,淨額 | 0 | 12.638 | 12.638 | 12.638 | |
無形資産,淨額 | 0 | 29 | 29 | 29 | |
長期投資 | 0 | 27.972 | |||
流動負債總額 | 16.296 | 16.073 | 24.433 | 24.44 | 18.472 |
應付賬款 | 2.493 | 2.659 | 4.598 | 1.731 | 3.693 |
預提費用 | 13.803 | 13.414 | 19.835 | 16.298 | 9.679 |
應付票據/短期債務 | 0 | 0 | 0 | 0 | 0 |
負債總額 | 19.13 | 22.131 | 42.676 | 66.69 | 57.392 |
長期債務總額 | 0 | 0 | 0 | 0 | 0 |
遞延所得稅 | 0 | 2.531 | 2.531 | 3.252 | |
總權益 | 82.664 | 168.929 | 240.578 | 273.217 | 210.653 |
Preferred Stock - Non Redeemable, Net | 0 | 0 | 0 | 0 | |
普通股 | 0.049 | 0.048 | 0.034 | 0.032 | 0.025 |
額外實收資本 | 807.938 | 800.728 | 742.387 | 712.807 | 552.762 |
留存收益(累計赤字) | -724.52 | -631.428 | -501.573 | -439.421 | -341.787 |
Unrealized Gain (Loss) | -0.803 | -0.419 | -0.27 | -0.201 | -0.347 |
總負債和股東權益 | 101.794 | 191.06 | 283.254 | 339.907 | 268.045 |
已發行普通股總數 | 48.895 | 48.1204 | 34.0267 | 32.5583 | 25.4954 |
應收賬款總額,淨額 | 0.944 | 0.336 | 1.23 | 3.374 | 2.43 |
應收賬款 - 貿易,淨額 | 0.944 | 0.336 | 1.23 | 3.374 | 2.43 |
其他流動負債,總計 | 0 | 6.411 | 5.1 | ||
其他負債,總計 | 2.834 | 6.058 | 15.712 | 39.719 | 35.668 |
其他長期資産,總計 | 0.889 | 1.703 | 6.392 | 1.684 | 3.348 |
Total Preferred Shares Outstanding | 0 | 0 | 0 | 0 | 0 |
Sep 2023 | Jun 2023 | Mar 2023 | Dec 2022 | Sep 2022 | |
---|---|---|---|---|---|
流動資産總額 | 49.672 | 64.081 | 79.744 | 96.967 | 115.078 |
現金和短期投資 | 46.21 | 59.831 | 73.016 | 91.61 | 108.651 |
現金等價物 | 26.656 | 21.623 | 43.482 | 52.418 | 54.673 |
短期投資 | 19.554 | 38.208 | 29.534 | 39.192 | 53.978 |
應收賬款總額,淨額 | 0 | 0.342 | 0.717 | 0.944 | 1.246 |
應收賬款 - 貿易,淨額 | 0 | 0.342 | 0.717 | 0.944 | 1.246 |
預付的費用 | 3.462 | 3.908 | 6.011 | 4.413 | 5.181 |
總資産 | 51.629 | 66.577 | 83.116 | 101.794 | 121.516 |
物業/廠房/設備,總計 - 淨額 | 1.405 | 2.164 | 3.038 | 3.938 | 4.825 |
商譽,淨額 | |||||
無形資産,淨額 | |||||
其他長期資産,總計 | 0.552 | 0.332 | 0.334 | 0.889 | 1.613 |
流動負債總額 | 7.132 | 8.831 | 9.97 | 16.296 | 15.461 |
應付賬款 | 0.758 | 0.904 | 1.224 | 2.493 | 1.942 |
預提費用 | 6.374 | 7.927 | 8.746 | 13.803 | 13.519 |
應付票據/短期債務 | 0 | 0 | 0 | 0 | 0 |
負債總額 | 9.915 | 11.628 | 12.783 | 19.13 | 19.112 |
長期債務總額 | 0 | 0 | 0 | 0 | 0 |
遞延所得稅 | |||||
其他負債,總計 | 2.783 | 2.797 | 2.813 | 2.834 | 3.651 |
總權益 | 41.714 | 54.949 | 70.333 | 82.664 | 102.404 |
普通股 | 0.053 | 0.052 | 0.052 | 0.049 | 0.048 |
額外實收資本 | 816.722 | 815.588 | 814.264 | 807.938 | 805.48 |
留存收益(累計赤字) | -774.786 | -760.366 | -743.47 | -724.52 | -702.125 |
Unrealized Gain (Loss) | -0.275 | -0.325 | -0.513 | -0.803 | -0.999 |
總負債和股東權益 | 51.629 | 66.577 | 83.116 | 101.794 | 121.516 |
已發行普通股總數 | 52.6142 | 52.4507 | 52.0153 | 48.895 | 48.4812 |
Preferred Stock - Non Redeemable, Net | 0 | 0 | 0 | 0 | 0 |
長期投資 | 0 | 0 | |||
物業/廠房/設備,總計 - 總額 | 5.625 | ||||
累計折舊,總計 | -1.687 | ||||
Total Preferred Shares Outstanding | 0 | 0 | 0 | 0 | 0 |
- 年度
- 每季度
2022 | 2021 | 2020 | 2019 | 2018 | |
---|---|---|---|---|---|
净收入/起跑线 | -93.092 | -129.855 | -62.152 | -97.634 | -90.751 |
经营活动产生的现金 | -84.463 | -93.396 | -62.957 | -84.067 | -64.958 |
经营活动产生的现金 | 0.498 | 0.466 | 0.691 | 0.494 | 0.643 |
Deferred Taxes | 0 | -2.531 | 0 | -0.774 | 1.099 |
非现金物品 | 10.253 | 49.925 | 28.813 | 23.374 | 28.256 |
营运资金的变化 | -2.122 | -11.401 | -30.309 | -9.527 | -4.205 |
投资活动产生的现金 | 90.64 | 26.515 | 68.07 | -50.318 | -135.397 |
资本支出 | -0.102 | -3.096 | -2.22 | -1.554 | -0.34 |
其他投资现金流量项目,总计 | 90.742 | 29.611 | 70.29 | -48.764 | -135.057 |
融资活动产生的现金 | 0.614 | 53.064 | 7.599 | 139.646 | 159.793 |
股票的发行(报废),净额 | 0.614 | 52.806 | 6.919 | 138.899 | 159.385 |
现金净变化 | 6.791 | -13.817 | 12.712 | 5.261 | -40.562 |
融资现金流项目 | 0.258 | 0.68 | 0.747 | 0.408 |
Mar 2023 | Dec 2022 | Sep 2022 | Jun 2022 | Mar 2022 | |
---|---|---|---|---|---|
Net income/Starting Line | -18.95 | -93.092 | -70.697 | -47.552 | -23.091 |
Cash From Operating Activities | -23.428 | -84.463 | -65.209 | -45.387 | -27.502 |
Cash From Operating Activities | 0.124 | 0.498 | 0.374 | 0.24 | 0.12 |
Non-Cash Items | 2.638 | 10.253 | 7.458 | 5.022 | 2.485 |
Changes in Working Capital | -7.24 | -2.122 | -2.344 | -3.097 | -7.016 |
Cash From Investing Activities | 10 | 90.64 | 74.078 | 42.646 | 33.049 |
Capital Expenditures | -0.102 | -0.102 | 0 | 0 | |
Other Investing Cash Flow Items, Total | 10 | 90.742 | 74.18 | 42.646 | 33.049 |
Cash From Financing Activities | 4.492 | 0.614 | 0.177 | 0.177 | 0 |
Issuance (Retirement) of Stock, Net | 4.492 | 0.614 | 0.177 | 0.177 | 0 |
Net Change in Cash | -8.936 | 6.791 | 9.046 | -2.564 | 5.547 |
Deferred Taxes | 0 | ||||
Financing Cash Flow Items |
差價合約交易計算器
如果您在特定日期(選取一個日期)開立差價合約交易並在不同日期(選取一個日期)關閉交易,計算您的假設盈虧。
交易佣金
0
- 1:1
杠杆
1:1
- 20
- 100
- 500
- 1000
- 10000
投資
交易規模(槓桿 x 投資):
打開
關閉
做空 做多
Assembly Biosciences, Inc. Company profile
关于 Assembly Biosciences Inc.
Assembly Biosciences, Inc.是一家处于临床阶段的生物技术公司,正在推进治疗慢性乙型肝炎病毒(HBV)感染的一类口服候选疗法。 公司的候选抑制剂产品包括Vebicorvir(VBR)、ABI-H2158(2158)和ABI-H3733(3733)。 Vebicorvir(VBR)是由印第安纳大学授权,用VBR加核苷酸类似物逆转录酶抑制剂(NrtIs)治疗患者,并最终过渡到患者。 ABI-H2158(2158)在化学上与VBR不同。 ABI-H3733(3733)用于中华人民共和国、香港、台湾和澳门(地区)的慢性HBV感染。 公司的研究和开发项目追求的是抑制HBV复制周期和阻断共价闭合环状DNA(cccDNA)生成的多种候选药物,以发现和开发HBV患者的有限和治愈性疗法。
Industry: | Proprietary & Advanced Pharmaceuticals |
Two Tower Place
7Th Floor
SOUTH SAN FRANCISCO
CALIFORNIA 94080
US
收入報表
- Annual
- Quarterly
人們也觀看
还在找一位您可以信任的经纪商吗?
加入成为全球580,000万多名交易者的一份子,选择利用Capital.com进行交易吧。